RT Journal Article
SR Electronic
T1 Combination of Genistein and Cisplatin with Two Designed Monofunctional Platinum Agents in Human Ovarian Tumour Models
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 6027
OP 6039
VO 35
IS 11
A1 LAILA ARZUMAN
A1 PHILIP BEALE
A1 NICK PROSCHOGO
A1 JUN Q. YU
A1 FAZLUL HUQ
YR 2015
UL http://ar.iiarjournals.org/content/35/11/6027.abstract
AB A great amount of research effort has been directed at platinum compounds that bind with DNA differently from cisplatin with the idea that the difference may translate into an altered spectrum of activity. Recently research has also been directed at applying combinations of platinum agents with tumour-active phytochemicals with the aim of providing a means of overcoming platinum resistance in ovarian cancer. Herein we report the synthesis of monofunctional platinum tris(3-hydroxypyridine)chloroplatinum(II) chloride (coded as LH1) and tris(imidazole)chloroplatinum(II) chloride (coded as LH2), and their activity alone and in combination with genistein and cisplatin against human ovarian A2780, cisplatin-resistant A2780cisR and picoplatin-resistant A2780ZD0473R cancer cell lines. Although both LH1 and LH2 were found to be less active than cisplatin against the tumour models, they produced synergistic outcomes in combination with genistein. Both the level of cellular accumulation of Pt and of Pt–DNA binding resulting from the combination were greater in the A2780cisR cell line than in the parental A2780 cell line, irrespective of the sequence of administration. Absence of association between activity of LH1 and LH2 and the level of Pt–DNA binding indicates that the cell death induced by LH1 and LH2 may not be limited to the effect of their binding with DNA.